Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940378 | 0.74 | MAP4K4 (0.41) | CYP17A1KDM4EHTTPIK3C3PDE10A | |
| SCHEMBL1828291 | 0.74 | SCN9A (0.42) | CYP17A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2487633 | 0.74 | PIK3C3 (0.40) | CYP17A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL3509699 | 0.74 | CYP17A1 (0.35) | CYP17A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL11385049 | 0.74 | CYP17A1 (0.35) | CYP17A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL11996694 | 0.74 | MAP4K4 (0.41) | CYP17A1KDM4EHTTPIK3C3PDE10A | |
| SCHEMBL29205649 | 0.74 | IDO1 (0.50) | CYP17A1KDM4EHTTIDO1PDE10A | |
| SCHEMBL10274928 | 0.74 | CHRNA7 (0.47) | CYP17A1KDM4EHTTPIK3C3IDO1 | |
| SCHEMBL20028256 | 0.72 | PIK3C3 (0.40) | CYP17A1KDM4EHTTPIK3C3IDO1 | |
| SCHEMBL29648000 | 0.71 | USP30 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061813-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-06-04 | — | — | EP | disclosed |
| WO-2023191469-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | 주식회사 비엔에이치리서치 | 2023-10-05 | — | — | WO | disclosed |
| EP-4061813-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2022-09-28 | — | — | EP | disclosed |
| US-20220289746-A1 | PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-09-15 | — | — | US | disclosed |
| CN-114728964-A | Pyrrolidine derivatives | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021099527-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-27 | — | — | WO | disclosed |
| CN-105636961-B | piperazine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2019-11-05 | — | — | CN | disclosed |
| CN-106459029-B | Indolin-2-one or pyrrolo-pyridine -2- ketone derivatives | 豪夫迈·罗氏有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-105308039-B | Indolin-2-one or pyrrolo-pyridine/pyrimid-2-one derivative | 豪夫迈·罗氏有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-106103426-B | 8- (piperazine -1- base) -1,2,3,4- tetrahydro-isoquinoline derivative | 爱杜西亚药品有限公司 | 2019-03-19 | — | — | CN | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-7655664-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| CN-101119987-A | Novel compounds | ASTRAZENECA AB GABOS BALINT (SE) | 2008-02-06 | — | — | CN | disclosed |
| EP-1831199-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | CYP17A1 1757/4885ADORA3 326/4885ADORA2A 359/4885 |
| US-20220289746-A1 | PYRROLIDINE DERIVATIVES | PRMT5, REV1, PARP1 | CYP17A1 2059/4885ADORA3 421/4885ADORA2A 789/4885 |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | CYP17A1 1757/4885ADORA3 326/4885ADORA2A 359/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CYP17A1 4025/4885ADORA3 156/4885ADORA2A 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.